CN Patent

CN108697807B — 代谢功能障碍引起的肿瘤的治疗

Assigned to SynDevRX Inc · Expires 2021-11-26 · 4y expired

What this patent protects

本公开内容涉及修饰的或聚合物缀合的MetAP2抑制剂。本公开内容还涉及治疗代谢引起的疾病和病症，例如某些癌症的方法。

USPTO Abstract

本公开内容涉及修饰的或聚合物缀合的MetAP2抑制剂。本公开内容还涉及治疗代谢引起的疾病和病症，例如某些癌症的方法。

Drugs covered by this patent

ribociclib-succinate (RIBOCICLIB SUCCINATE)

Patent Metadata

Patent number: CN108697807B
Jurisdiction: CN
Classification: —
Expires: 2021-11-26
Drug substance claim: No
Drug product claim: No
Assignee: SynDevRX Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.